- Home
- CNNE vs AUPH Comparison
CNNE vs AUPH Comparison
Compare CNNE & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNNE
- AUPH
- Stock Information
- Founded
- CNNE 2014
- AUPH 1993
- Country
- CNNE United States
- AUPH Canada
- Employees
- CNNE N/A
- AUPH N/A
- Industry
- CNNE Restaurants
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- CNNE Consumer Discretionary
- AUPH Health Care
- Exchange
- CNNE Nasdaq
- AUPH Nasdaq
- Market Cap
- CNNE 1.2B
- AUPH 1.4B
- IPO Year
- CNNE N/A
- AUPH 1999
- Fundamental
- Price
- CNNE $20.30
- AUPH $11.71
- Analyst Decision
- CNNE Buy
- AUPH Strong Buy
- Analyst Count
- CNNE 3
- AUPH 4
- Target Price
- CNNE $23.33
- AUPH $12.25
- AVG Volume (30 Days)
- CNNE 618.2K
- AUPH 2.5M
- Earning Date
- CNNE 08-11-2025
- AUPH 07-31-2025
- Dividend Yield
- CNNE 2.32%
- AUPH N/A
- EPS Growth
- CNNE N/A
- AUPH N/A
- EPS
- CNNE N/A
- AUPH 0.42
- Revenue
- CNNE $445,000,000.00
- AUPH $260,111,000.00
- Revenue This Year
- CNNE N/A
- AUPH $12.15
- Revenue Next Year
- CNNE $2.03
- AUPH $18.34
- P/E Ratio
- CNNE N/A
- AUPH $27.26
- Revenue Growth
- CNNE N/A
- AUPH 25.59
- 52 Week Low
- CNNE $15.92
- AUPH $5.20
- 52 Week High
- CNNE $22.36
- AUPH $11.47
- Technical
- Relative Strength Index (RSI)
- CNNE 44.52
- AUPH 79.52
- Support Level
- CNNE $20.66
- AUPH $8.73
- Resistance Level
- CNNE $21.86
- AUPH $9.37
- Average True Range (ATR)
- CNNE 0.32
- AUPH 0.50
- MACD
- CNNE -0.18
- AUPH 0.25
- Stochastic Oscillator
- CNNE 11.15
- AUPH 92.68
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.